{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:21:23Z","timestamp":1783606883953,"version":"3.55.0"},"reference-count":28,"publisher":"Bioscientifica","issue":"2","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82141104"],"award-info":[{"award-number":["82141104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:p>Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms characterized by heterogeneous clinical and genetic profiles. Evidence regarding the efficacy of systemic therapies in this population remains limited. We retrospectively reviewed 157 PPGL patients treated at our center between 2021 and 2024. Clinical, pathological, genetic, and treatment data were collected. Outcomes of targeted therapy, chemotherapy, and somatostatin analogs (SSAs) were analyzed, including progression-free survival (PFS). We found that among the 113 patients who underwent next-generation sequencing, 47.8% harbored pathogenic variant, with SDHB being the most frequent. In the overall cohort, median PFS for targeted therapy, chemotherapy, and SSAs was 8.02, 5.06, and 16.03 months, respectively. For the most frequently used agents in each category \u2013 surufatinib, temozolomide-based chemotherapy, and lanreotide \u2013 median PFS was 13.08, 10.05, and 19.02 months, respectively (P = 0.46). In the first-line setting, targeted therapy and SSAs demonstrated superior efficacy compared with chemotherapy (median PFS 20.01 and 15.05 vs 4.07 months; P &amp;lt; 0.05), with no significant difference observed between surufatinib and lanreotide. In patients with SDHx pathogenic variant versus SDHx normal patient, the mPFS with lanreotide was 15.05 vs 22.05 months and, with temozolomide chemotherapy, was 11.01 vs 7.04 months; neither comparison showed a statistically significant difference. In the first-line setting, targeted therapy and SSAs were associated with longer PFS than chemotherapy, with surufatinib and lanreotide showing favorable disease control. SDHx pathogenic variant status did not show a clear association with response to TKIs or temozolomide, underscoring the need for validation in larger cohorts.<\/jats:p>","DOI":"10.1530\/erc-25-0437","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:26:43Z","timestamp":1768566403000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["Systemic therapy for advanced pheochromocytoma and paraganglioma: real-world evidence from a single-center cohort"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3759-2997","authenticated-orcid":true,"given":"Yun","family":"Liang","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Xu","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichen","family":"Sun","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3510-5921","authenticated-orcid":true,"given":"Luohai","family":"Chen","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"1"},{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026070909443795100_bib1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026070909443795100_bib2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","article-title":"Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas","volume":"23","author":"Garcia-Carbonero","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"2026070909443795100_bib3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MED.0000000000000330","article-title":"Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials","volume":"24","author":"Roman-Gonzalez","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2026070909443795100_bib4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909443795100_bib5","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s40618-021-01649-7","article-title":"Protocol for presurgical and anesthetic management of pheochromocytomas and sympathetic paragangliomas: a multidisciplinary approach","volume":"44","author":"Araujo-Castro","year":"2021","journal-title":"J Endocrinol Investig"},{"key":"2026070909443795100_bib6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/cancers14030594","article-title":"New insights on the genetics of pheochromocytoma and paraganglioma and its clinical implications","volume":"14","author":"Jhawar","year":"2022","journal-title":"Cancers"},{"key":"2026070909443795100_bib7","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909443795100_bib8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic sdhb and sporadic pheochromocytoma\/paraganglioma: an national institutes of health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr Pract"},{"key":"2026070909443795100_bib9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jso.24553","article-title":"Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas","volume":"115","author":"Nastos","year":"2017","journal-title":"J Surg Oncol"},{"key":"2026070909443795100_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/a-0715-1888","article-title":"Metastatic phaeochromocytoma: spinning towards more promising treatment options","volume":"127","author":"N\u00f6lting","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2026070909443795100_bib11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.185","article-title":"Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas","volume":"13","author":"NGS in PPGL (NGSnPPGL) Study Group","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"2026070909443795100_bib12","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1530\/ERC-20-0043","article-title":"Antiangiogenic therapies for pheochromocytoma and paraganglioma","volume":"27","author":"Jimenez","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"2026070909443795100_bib13","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O\u2019Kane","year":"2019","journal-title":"Br J Cancer"},{"key":"2026070909443795100_bib14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet"},{"key":"2026070909443795100_bib15","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070909443795100_bib16","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070909443795100_bib17","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909443795100_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"2026070909443795100_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouze","year":"2013","journal-title":"Cancer Cell"},{"key":"2026070909443795100_bib20","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1210\/clinem\/dgac471","article-title":"Targeted therapies in pheochromocytoma and paraganglioma","volume":"107","author":"Wang","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909443795100_bib21","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1210\/clinem\/dgad166","article-title":"Metastatic pheochromocytoma and paraganglioma: somatostatin receptor 2 expression, genetics, and therapeutic responses","volume":"108","author":"Fischer","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909443795100_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","article-title":"Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants","volume":"11","author":"Taieb","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070909443795100_bib23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement","volume":"20","author":"Taieb","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026070909443795100_bib24","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"key":"2026070909443795100_bib25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/ERC-21-0392","article-title":"SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma","volume":"29","author":"Perez","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"2026070909443795100_bib26","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070909443795100_bib27","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41598-018-25169-2","article-title":"Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (temozolomide)","volume":"8","author":"Pandith","year":"2018","journal-title":"Sci Rep"},{"key":"2026070909443795100_bib28","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S1470-2045(09)70164-0","article-title":"An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis","volume":"10","author":"van Nederveen","year":"2009","journal-title":"Lancet Oncol"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/33\/2\/ERC-25-0437.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/33\/2\/ERC-25-0437.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0437\/505946\/erc-25-0437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0437\/505946\/erc-25-0437.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:44:44Z","timestamp":1783604684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/2\/e250437\/75533\/Systemic-therapy-for-advanced-pheochromocytoma-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0437","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"e250437"}}